A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD

PHASE3CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

November 30, 2013

Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

Recombinant Human VEGF Receptor-Fc Fusion Protein

Intravitreal injection of KH902 once per month

Trial Locations (11)

110001

The First Hospital of China Medical University, Shenyang

200031

Eye & ENT Hospital of Fudan University, Shanghai

200080

Shanghai First People's Hospital, Shanghai

214002

Wuxi Second People's Hospital, Wuxi

266071

Ophthalmologic Hospital of Qingdao, Qingdao

325027

Affiliated Hospital of Wenzhou Medical College, Wenzhou

350005

First Affiliated Hospital of Fujian Medical College, Fuzhou

400042

Daping Hospital of the Third Military Medical University, Chongqing

430060

People's Hospital of Wuhan University, Wuhan

430070

Wuhan General Hospital of Guangzhou Military Command, Wuhan

515041

Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong, Shantou

All Listed Sponsors
collaborator

University of Wisconsin, Madison

OTHER

lead

Chengdu Kanghong Biotech Co., Ltd.

INDUSTRY

NCT01436864 - A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD | Biotech Hunter | Biotech Hunter